Rockwell Medical SFP Meets Primary and Key Secondary Endpoints in Phase 3 CRUISE-1 Efficacy Study
July 11, 2013 at 06:54 AM EDT
Rockwell Medical (NASDAQ: RMTI ) today announced successful top-line results from the long-term CRUISE-1 Phase 3 efficacy study of SFP. SFP is the Company's late-stage investigational iron-delivery drug for the treatment of iron deficiency in chronic kidney disease patients receiving hemodialysis. In the Phase 3 efficacy study, SFP met
